agilon health, inc.

AGL

HealthcareSmall CapUS Equities · NYSE / NASDAQ

AI Agents

Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.

Valuation

Market Cap$1.6B

Current Price$106.84as of Jun 23, 2026

P/E Ratio-

P/B Ratio12.54

EV / EBITDA-

EV / Sales0.23

Profitability

Operating Margin-7.2%

Net Profit Margin-6.6%

EBITDA Margin-6.2%

Returns

ROE-308.8%

ROCE-245.8%

ROIC %-

ROA-30.8%

Solvency

Current Ratio1.02

Debt / Equity0.29

Debt / Assets0.03

CFO / Net Profit0.27

Price History▲ 98.77% over 1Y

Technical Chart

Historical Performance Charts

5-year financial trends. Figures in USD millions.

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Latest fiscal year: 2025

Revenue$5.9B▼ 2.1%

EBITDA$-369M▲ 69.1%

Net Profit$-391M▲ 50.4%

Cash from Ops (CFO)$-106M▲ 83.1%

Free Cash Flow (FCF)$-149M▲ 50.3%

Revenue CAGR 3Y35.4%

Revenue CAGR 5Y-

Net Profit CAGR 3Y-

Net Profit CAGR 5Y-

Historical Growth

Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)

Year	Revenue	EBITDA	Net Profit	FCF	ROE	Rev Growth 1Y	NP Growth 1Y
2025	$5.9B	$-369M	$-391M	$-149M	-308.8%	-2.1%	50.4%
2024	$6.1B	$-218M	$-260M	$-99M	-55.2%	40.4%	-0.9%
2023	$4.3B	$-168M	$-263M	$-187M	-39.7%	80.7%	146.4%
2022	$2.4B	$-72M	$-107M	$-163M	-10.2%	-	-
2021	-	-

Financial Statements

Income statement, balance sheet, and cash flow as reported

Consolidated Figures in USD Millions.

Metric	2021	2022	2023	2024	2025
Total Revenue	-	2,388.22	4,316.36	6,060.53	5,932.58
Operating Revenue	-	2,384.89	4,307.35	6,047.72	5,921.34
Cost Of Revenue	-	2,276.86	4,246.69	6,055.69	6,092.60
Gross Profit	-	111.36	69.67	4.84	-160.02
Operating Expense	-	216.74	301.80	293.38	267.13
Selling General And Administration	-	207.79	285.76	268.91	238.54
Total Expenses	-	2,493.60	4,548.50	6,349.06	6,359.73
Operating Income	-	-105.38	-232.13	-288.53	-427.15
Total Operating Income As Reported	-	-105.38	-232.13	-292.13	-463.24
EBITDA	-	-72.41	-167.64	-218.19	-368.86
Normalized EBITDA	-	-66.96	-167.64	-214.59	-332.78
EBIT	-	-86.19	-187.80	-242.65	-397.46
Interest Expense	-	4.48	6.66	6.18	6.64
Net Interest Income	-	-4.48	-6.66	-6.18	-6.64
Other Non Operating Income Expenses	-	13.93	27.84	34.49	67.62
Other Income Expense	-	19.19	44.33	45.88	29.70
Interest Expense Non Operating	-	4.48	6.66	6.18	6.64
Net Non Operating Interest Income Expense	-	-4.48	-6.66	-6.18	-6.64
Pretax Income	-	-90.67	-194.46	-248.83	-404.10
Tax Provision	-	1.64	0.79	1.45	1.25
Tax Rate For Calcs	-	0	0	0	0
Tax Effect Of Unusual Items	-	-1.15	0	-0.76	0
Net Income Continuous Operations	-	-92.31	-195.25	-250.28	-405.35
Net Income From Continuing And Discontinued Operation	-	-106.55	-262.60	-260.15	-391.35
Net Income From Continuing Operation Net Minority Interest	-	-92	-195.05	-250.33	-405.35
Net Income	-	-106.55	-262.60	-260.15	-391.35
Net Income Common Stockholders	-	-106.55	-262.60	-260.15	-391.35
Net Income Including Noncontrolling Interests	-	-106.86	-262.80	-260.10	-391.35
Normalized Income	-	-87.69	-195.05	-247.49	-369.26
Diluted NI Availto Com Stockholders	-	-106.55	-262.60	-260.15	-391.35
Basic Average Shares	-	16.33	16.36	16.44	16.56
Diluted Average Shares	-	16.33	16.36	16.44	16.56
Reconciled Depreciation	-	13.77	20.16	24.46	28.59
Reconciled Cost Of Revenue	-	2,272.04	4,242.58	6,055.69	6,092.60
Total Unusual Items	-	-5.46	0	-3.60	-36.08
Total Unusual Items Excluding Goodwill	-	-5.46	0	-3.60	-36.08
Minority Interests	-	0.31	0.21	-0.05	0
Net Income Discontinuous Operations	-	-14.55	-67.55	-9.82	14
Special Income Charges	-	-5.46	0	-3.60	-36.08
Other Special Charges	-	5.46	-	-	-
Write Off	-	0	0	3.60	36.08
Depreciation Amortization Depletion Income Statement	-	8.95	16.04	24.46	28.59
Depreciation And Amortization In Income Statement	-	8.95	16.04	24.46	28.59
General And Administrative Expense	-	207.79	285.76	268.91	238.54
Other Gand A	-	207.79	285.76	268.91	238.54
Earnings From Equity Interest	-	10.72	16.49	14.99	-1.84

Peer Comparison

Healthcare sector peers, ranked by market cap

Company	Ticker	Market Cap	P/E	P/B	ROE	EV/EBITDA
agilon health, inc.this co.	AGL	$1.6B	-	12.54	-308.8%	-
Fortrea Holdings Inc.	FTRE	$1.6B	-	2.90	-175.0%	-
Capricor Therapeutics, Inc.	CAPR	$1.6B	-15.41	5.29	-34.4%	-13.44
Tyra Biosciences, Inc.	TYRA	$1.6B	-13.48	6.24	-46.3%	-11.68
Syndax Pharmaceuticals, Inc.	SNDX	$1.6B	-5.59

Learn while you research

Hand-picked academy chapters to deepen your understanding of agilon health, inc. and the metrics that matter.

01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read 02 Stock Market Risks

Loading…

Year

Revenue

EBITDA

Net Profit

FCF

ROE

Rev Growth 1Y

NP Growth 1Y

2025

$5.9B

$-369M

$-391M

$-149M

-308.8%

-2.1%

50.4%

2024

$6.1B

$-218M

$-260M

$-99M

-55.2%

40.4%

-0.9%

2023

$4.3B

$-168M

$-263M

$-187M

-39.7%

80.7%

146.4%

2022

$2.4B

$-72M

$-107M

$-163M

-10.2%

2021

Metric

2021

2022

2023

2024

2025

Total Revenue

2,388.22

4,316.36

6,060.53

5,932.58

Operating Revenue

2,384.89

4,307.35

6,047.72

5,921.34

Cost Of Revenue

2,276.86

4,246.69

6,055.69

6,092.60

Gross Profit

111.36

69.67

4.84

-160.02

Operating Expense

216.74

301.80

293.38

267.13

Selling General And Administration

207.79

285.76

268.91

238.54

Total Expenses

2,493.60

4,548.50

6,349.06

6,359.73

Operating Income

-105.38

-232.13

-288.53

-427.15

Total Operating Income As Reported

-105.38

-232.13

-292.13

-463.24

EBITDA

-72.41

-167.64

-218.19

-368.86

Normalized EBITDA

-66.96

-167.64

-214.59

-332.78

EBIT

-86.19

-187.80

-242.65

-397.46

Interest Expense

4.48

6.66

6.18

6.64

Net Interest Income

-4.48

-6.66

-6.18

-6.64

Other Non Operating Income Expenses

13.93

27.84

34.49

67.62

Other Income Expense

19.19

44.33

45.88

29.70

Interest Expense Non Operating

4.48

6.66

6.18

6.64

Net Non Operating Interest Income Expense

-4.48

-6.66

-6.18

-6.64

Pretax Income

-90.67

-194.46

-248.83

-404.10

Tax Provision

1.64

0.79

1.45

1.25

Tax Rate For Calcs

Tax Effect Of Unusual Items

-1.15

-0.76

Net Income Continuous Operations

-92.31

-195.25

-250.28

-405.35

Net Income From Continuing And Discontinued Operation

-106.55

-262.60

-260.15

-391.35

Net Income From Continuing Operation Net Minority Interest

-92

-195.05

-250.33

-405.35

Net Income

-106.55

-262.60

-260.15

-391.35

Net Income Common Stockholders

-106.55

-262.60

-260.15

-391.35

Net Income Including Noncontrolling Interests

-106.86

-262.80

-260.10

-391.35

Normalized Income

-87.69

-195.05

-247.49

-369.26

Diluted NI Availto Com Stockholders

-106.55

-262.60

-260.15

-391.35

Basic Average Shares

16.33

16.36

16.44

16.56

Diluted Average Shares

16.33

16.36

16.44

16.56

Reconciled Depreciation

13.77

20.16

24.46

28.59

Reconciled Cost Of Revenue

2,272.04

4,242.58

6,055.69

6,092.60

Total Unusual Items

-5.46

-3.60

-36.08

Total Unusual Items Excluding Goodwill

-5.46

-3.60

-36.08

Minority Interests

0.31

0.21

-0.05

Net Income Discontinuous Operations

-14.55

-67.55

-9.82

Special Income Charges

-5.46

-3.60

-36.08

Other Special Charges

5.46

Write Off

3.60

36.08

Depreciation Amortization Depletion Income Statement

8.95

16.04

24.46

28.59

Depreciation And Amortization In Income Statement

8.95

16.04

24.46

28.59

General And Administrative Expense

207.79

285.76

268.91

238.54

Other Gand A

207.79

285.76

268.91

238.54

Earnings From Equity Interest

10.72

16.49

14.99

-1.84

Company

Ticker

Market Cap

P/E

P/B

ROE

EV/EBITDA

agilon health, inc.this co.

AGL

$1.6B

12.54

-308.8%

Fortrea Holdings Inc.

FTRE

$1.6B

2.90

-175.0%

Capricor Therapeutics, Inc.

CAPR

$1.6B

-15.41

5.29

-34.4%

-13.44

Tyra Biosciences, Inc.

TYRA

$1.6B

-13.48

6.24

-46.3%

-11.68

Syndax Pharmaceuticals, Inc.

SNDX

$1.6B

-5.59

agilon health, inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

agilon health, inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Key concepts to brush up on